PACB - Pacific Biosciences of California Stock Price, Fair Value and News

2.03USD-0.16 (-7.31%)Delayed

Market Summary

USD2.03-0.16

Delayed

-7.31%

PACB Alerts

Losses in recent quarter

PACB Stock Price

View Fullscreen

PACB RSI Chart

PACB Valuation

Market Cap

552.9M

Price/Earnings (Trailing)

-1.86

Price/Sales (Trailing)

2.76

EV/EBITDA

-1.68

Price/Free Cashflow

-2.22

PACB Price/Sales (Trailing)

PACB Profitability

Operating Margin

27.09%

EBT Margin

-153.83%

Return on Equity

-45.75%

Return on Assets

-17.78%

Free Cashflow Yield

-45.07%

PACB Fundamentals

PACB Revenue

Revenue (TTM)

200.4M

Rev. Growth (Yr)

-0.23%

Rev. Growth (Qtr)

-33.5%

PACB Earnings

Earnings (TTM)

-296.9M

Earnings Growth (Yr)

11.18%

Earnings Growth (Qtr)

4.68%

Breaking Down PACB Revenue

Last 7 days

14.7%

Last 30 days

45%

Last 90 days

-64.6%

Trailing 12 Months

-84.0%

How does PACB drawdown profile look like?

PACB Financial Health

Current Ratio

9.28

Debt/Equity

Debt/Cashflow

-93.63

PACB Investor Care

Shares Dilution (1Y)

8.99%

Diluted EPS (TTM)

-1.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	200.4M	0	0	0
2023	134.0M	146.1M	169.5M	200.5M
2022	134.7M	139.5M	137.0M	128.3M
2021	92.3M	105.8M	121.6M	130.5M
2020	90.1M	82.5M	79.7M	78.9M
2019	75.7M	78.7M	82.5M	90.9M
2018	87.9M	89.4M	84.0M	78.6M
2017	96.5M	95.8M	94.3M	93.5M
2016	94.3M	90.1M	101.3M	90.7M
2015	66.6M	80.1M	73.4M	92.8M
2014	34.2M	39.6M	52.8M	60.6M
2013	21.5M	20.3M	24.9M	28.2M
2012	43.6M	40.3M	32.5M	26.0M
2011	9.7M	17.8M	25.8M	33.9M
2010	0	648.0K	1.2M	1.7M
2009	0	0	0	135.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pacific Biosciences of California

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	ordonez kathy	acquired	1,038,680	2.8723	361,621	-
Mar 06, 2024	meline david w	bought	176,160	4.404	40,000	-
Mar 04, 2024	farmer michele	sold	-14,457	4.871	-2,968	see remarks
Mar 04, 2024	van oene mark	sold	-44,745	4.871	-9,186	see remarks
Mar 04, 2024	henry christian o	sold	-69,056	4.871	-14,177	see remarks
Mar 04, 2024	kim susan g.	sold	-25,694	4.871	-5,275	see remarks
Mar 01, 2024	mohr marshall	acquired	111,250	4.45	25,000	-
Feb 22, 2024	eidel jeff	acquired	-	-	461,538	see remarks
Feb 22, 2024	farmer michele	acquired	-	-	115,384	see remarks
Feb 22, 2024	van oene mark	acquired	-	-	798,076	see remarks

Which funds bought or sold PACB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	6.9	-2,826,240	1,953,040	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.6	-1,579,950	906,829	-%
May 16, 2024	COMERICA BANK	reduced	-24.9	-40,928	16,481	-%
May 16, 2024	Arete Wealth Advisors, LLC	added	232	45,396	213,255	0.02%
May 15, 2024	ArrowMark Colorado Holdings LLC	added	100	-531,122	1,756,430	0.02%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	added	50.32	-300,838	406,365	-%
May 15, 2024	Mariner, LLC	added	88.81	-31,010	80,441	-%
May 15, 2024	VK Services, LLC	unchanged	-	-15,954,700	9,872,940	1.80%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	156	-14,156	707,595	-%
May 15, 2024	WATER ISLAND CAPITAL LLC	new	-	39,000	39,000	-%

Are Funds Buying or Selling PACB?

Are funds buying PACB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PACB

No. of Funds

PACB Alerts

Losses in recent quarter

Unveiling Pacific Biosciences of California's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	madrone capital partners, llc	6.6%	17,591,915	SC 13G/A
Feb 12, 2024	nikko asset management americas, inc.	4.93%	13,200,375	SC 13G/A
Feb 09, 2024	jackson square partners, llc	3.63%	9,704,766	SC 13G/A
Feb 05, 2024	sumitomo mitsui trust holdings, inc.	4.93%	13,200,375	SC 13G/A
Jan 29, 2024	ark investment management llc	12.90%	34,504,273	SC 13G/A
Jan 24, 2024	blackrock inc.	9.2%	24,642,666	SC 13G/A
Jan 10, 2024	vanguard group inc	10.02%	26,789,499	SC 13G/A
Feb 13, 2023	capital international investors	2.7%	6,099,681	SC 13G/A
Feb 13, 2023	madrone capital partners, llc	7.3%	16,415,933	SC 13G/A
Feb 10, 2023	nikko asset management americas, inc.	6.26%	14,166,193	SC 13G/A

Recent SEC filings of Pacific Biosciences of California

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 09, 2024	S-3ASR	S-3ASR
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 16, 2024	8-K	Current Report
Apr 15, 2024	PRE 14A	PRE 14A
Apr 11, 2024	POSASR	POSASR
Apr 11, 2024	POSASR	POSASR

Peers (Alternatives to Pacific Biosciences of California)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Pacific Biosciences of California News

Latest updates

Pacific Biosciences of California Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-33.5%	38,810,000	58,357,000	55,691,000	47,573,000	38,900,000	27,353,000	32,311,000	35,467,000	33,173,000	36,019,000	34,887,000	30,610,000	28,997,000	27,136,000	19,082,000	17,077,000	15,598,000	27,930,000	21,915,000	24,621,000	16,425,000
Cost Of Revenue	-43.6%	27,528,000	48,786,000	37,789,000	32,027,000	29,139,000	22,213,000	18,764,000	19,274,000	19,018,000	19,253,000	19,523,000	16,857,000	16,020,000	-	-	-	-	-	-	-	-
Gross Profit	17.9%	11,282,000	9,571,000	17,902,000	15,546,000	9,761,000	5,140,000	13,547,000	16,193,000	14,155,000	16,766,000	15,364,000	13,753,000	12,977,000	11,401,000	7,064,000	6,613,000	7,488,000	12,932,000	6,914,000	9,613,000	5,117,000
Operating Expenses	-4.6%	92,644,000	97,119,000	100,394,000	88,721,000	101,013,000	92,224,000	88,167,000	84,162,000	91,678,000	81,442,000	89,840,000	51,326,000	46,687,000	35,378,000	31,239,000	30,137,000	40,197,000	30,849,000	35,028,000	33,993,000	35,251,000
S&GA Expenses	-4.9%	43,753,000	45,996,000	43,431,000	40,573,000	39,818,000	45,003,000	36,795,000	39,252,000	39,804,000	37,319,500	31,606,000	29,060,000	26,139,000	17,953,000	14,772,000	15,127,000	24,947,000	16,576,000	20,066,000	19,083,000	19,766,000
R&D Expenses	-2.4%	43,455,000	44,544,000	47,514,000	46,173,000	48,939,000	42,623,000	47,092,000	50,348,000	52,937,000	42,576,500	27,508,000	22,266,000	20,548,000	17,425,000	16,467,000	15,010,000	15,250,000	14,273,000	14,962,000	14,910,000	15,485,000
EBITDA Margin	3.3%	-1.41	-1.46	-1.74	-2.01	-2.21	-2.26	-2.00	-1.98	-1.88	-1.95	0.37	0.39	-	-	-	-	-	-	-	-	-
Interest Expenses	0.1%	3,575,000	3,571,000	3,588,000	3,554,000	3,630,000	3,648,000	3,664,000	3,681,000	3,697,000	3,479,000	3,673,000	3,589,000	1,789,000	-	-	-	267,000	678,000	664,000	644,000	625,000
Income Taxes	100.0%	-	-718,000	-10,706,000	-	-	-	-	-	-	-	-94,824,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	5.5%	-78,178,000	-82,736,000	-77,575,000	-69,833,000	-88,015,000	-84,384,000	-76,971,000	-71,394,000	-81,499,000	-68,154,000	-78,282,000	-	-	-	-23,708,000	-	-	-	-	-	-
EBT Margin	3.0%	-1.54	-1.59	-1.89	-2.18	-2.39	-2.45	-2.18	-2.15	-2.04	-2.11	0.24	0.28	-	-	-	-	-	-	-	-	-
Net Income	4.7%	-78,178,000	-82,018,000	-66,869,000	-69,833,000	-88,015,000	-84,384,000	-76,971,000	-71,394,000	-81,499,000	-69,329,000	16,542,000	-41,001,000	-87,435,000	74,935,000	-23,708,000	-23,086,000	1,262,000	-91,000	-29,123,000	-24,596,000	-30,324,000
Net Income Margin	3.2%	-1.48	-1.53	-1.82	-2.18	-2.39	-2.45	-2.18	-1.47	-1.30	-1.39	-0.30	-0.73	-	-	-	-	-	-	-	-	-
Free Cashflow	-33.5%	-79,561,000	-59,584,000	-66,011,000	-44,009,000	-98,412,000	-65,470,000	-67,242,000	-64,582,000	-82,667,000	-34,550,000	-41,775,000	-17,281,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.4%	1,670	1,746	1,898	1,848	1,896	1,767	1,819	1,876	1,937	2,007	2,034	1,246	1,253	414	300	214	235	148	146	171	186
Current Assets	-8.8%	677	742	882	936	981	852	914	970	1,029	1,101	1,130	1,189	1,196	356	240	151	170	81.00	77.00	99.00	113
Cash Equivalents	-55.9%	79.00	180	386	209	354	325	304	310	429	461	425	460	932	86.00	69.00	43.00	69.00	34.00	33.00	30.00	38.00
Inventory	18.8%	67.00	57.00	68.00	68.00	62.00	50.00	43.00	36.00	30.00	25.00	18.00	18.00	16.00	14.00	16.00	17.00	16.00	13.00	15.00	17.00	20.00
Net PPE	2.4%	37.00	36.00	40.00	40.00	41.00	42.00	39.00	38.00	36.00	33.00	31.00	25.00	24.00	25.00	27.00	28.00	29.00	30.00	32.00	33.00	34.00
Goodwill	0.0%	462	462	464	410	410	410	410	410	410	410	391	-	-	-	-	-	-	-	-	-	-
Liabilities	-2.3%	1,021	1,045	1,135	1,206	1,204	1,204	1,192	1,194	1,202	1,216	1,193	988	972	78.00	171	172	174	93.00	95.00	95.00	91.00
Current Liabilities	-23.2%	73.00	95.00	184	271	266	263	82.00	84.00	61.00	72.00	56.00	45.00	34.00	39.00	130	131	132	49.00	51.00	49.00	45.00
Shareholder's Equity	-7.5%	649	701	764	642	692	563	627	682	735	791	841	258	281	335	129	41.00	60.00	55.00	51.00	76.00	95.00
Retained Earnings	-4.3%	-1,917	-1,839	-1,757	-1,690	-1,620	-1,532	-1,447	-1,370	-1,299	-1,218	-1,148	-1,165	-1,124	-1,036	-1,111	-1,088	-1,065	-1,066	-1,066	-1,037	-1,012
Additional Paid-In Capital	1.0%	2,566	2,540	2,522	2,335	2,314	2,100	2,081	2,058	2,038	2,010	1,989	1,423	1,405	1,372	1,241	1,129	1,125	1,121	1,117	1,113	1,107
Shares Outstanding	1.7%	272	268	258	250	250	227	225	223	222	204	202	197	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	3,324	-	-	-	992	-	-	-	6,791	-	-	-	499	-	-	-	855	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-31.5%	-75,682	-57,560	-65,181	-41,741	-94,691	-60,566	-63,053	-60,563	-79,029	-31,708	-40,656	-15,712	-23,104	-14,263	-17,808	-23,789	75,363	-18,180	-17,260	-17,559	-25,313
Share Based Compensation	17.7%	19,525	16,584	19,691	17,891	17,952	17,955	18,936	19,019	22,703	29,564	-	23,000	10,165	7,988	1,700	1,100	4,032	6,545	1,400	1,400	4,381
Cashflow From Investing	48.7%	-34,136	-66,575	242,323	-98,591	-72,553	80,403	53,908	-60,281	42,053	65,753	-291,646	-460,808	8,170	-98,495	-63,641	-2,859	-54,327	-3,408	19,659	7,812	37,984
Cashflow From Financing	108.0%	6,553	-81,602	-781	-4,715	195,989	819	3,133	455	5,215	1,324	299,656	2,880	865,721	125,877	107,135	628	18,199	18,131	327	1,400	6,690

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PACB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 38,810	$ 38,900
Cost of Revenue:
Amortization of acquired intangible assets	1,343	183
Total cost of revenue	27,528	29,139
Gross profit	11,282	9,761
Operating Expense:
Research and development	43,455	48,939
Sales, general and administrative	43,753	39,818
Amortization of acquired intangible assets	5,506	0
Change in fair value of contingent consideration	(70)	12,256
Total operating expense	92,644	101,013
Operating loss	(81,362)	(91,252)
Interest expense	(3,575)	(3,630)
Other income, net	6,759	6,867
Loss before benefit from income taxes	(78,178)	(88,015)
Benefit from income taxes	0	0
Net loss	(78,178)	(88,015)
Other comprehensive (loss) income:
Unrealized (loss) gain on investments	(525)	2,841
Comprehensive loss	$ (78,703)	$ (85,174)
Net loss per share:
Basic (in dollars per share)	$ (0.29)	$ (0.36)
Diluted (in dollars per share)	$ (0.29)	$ (0.36)
Weighted average shares outstanding used in calculating net loss per share:
Basic (in shares)	269,578	242,032
Diluted (in shares)	269,578	242,032
Product revenue
Revenue:
Total revenue	$ 35,009	$ 34,654
Cost of Revenue:
Cost of revenue	22,447	25,164
Service and other revenue
Revenue:
Total revenue	3,801	4,246
Cost of Revenue:
Cost of revenue	$ 3,738	$ 3,792

PACB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 76,646	$ 179,911
Investments	485,268	451,505
Accounts receivable, net	30,323	36,615
Inventory, net	67,343	56,676
Prepaid expenses and other current assets	17,144	17,040
Short-term restricted cash	300	300
Total current assets	677,024	742,047
Property and equipment, net	37,291	36,432
Operating lease right-of-use assets, net	30,672	32,593
Long-term restricted cash	2,422	2,422
Intangible assets, net	450,131	456,984
Goodwill	462,261	462,261
Other long-term assets	10,119	13,274
Total assets	1,669,920	1,746,013
Current liabilities
Accounts payable	21,006	15,062
Accrued expenses	21,991	45,708
Deferred revenue, current	17,346	16,342
Operating lease liabilities, current	9,772	9,591
Other liabilities, current	2,836	8,326
Total current liabilities	72,951	95,029
Deferred revenue, non-current	6,127	5,530
Contingent consideration liability, non-current	19,480	19,550
Operating lease liabilities, non-current	29,049	31,606
Convertible senior notes, net, non-current	892,545	892,243
Other liabilities, non-current	751	751
Total liabilities	1,020,903	1,044,709
Commitments and contingencies
Stockholders’ equity
Authorized 50,000 shares; No shares issued or outstanding	0	0
Authorized 1,000,000 shares; issued and outstanding 272,280 and 267,744 shares at March 31, 2024 and December 31, 2023, respectively	272	268
Additional paid-in capital	2,566,304	2,539,892
Accumulated other comprehensive (loss) income	(306)	219
Accumulated deficit	(1,917,253)	(1,839,075)
Total stockholders’ equity	649,017	701,304
Total liabilities and stockholders’ equity	$ 1,669,920	$ 1,746,013

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

CEO	Mr. Christian O. Henry M.B.A.
WEBSITE	pacb.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	769

Pacific Biosciences of California Frequently Asked Questions

What is the ticker symbol for Pacific Biosciences of California? What does PACB stand for in stocks?

PACB is the stock ticker symbol of Pacific Biosciences of California. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pacific Biosciences of California (PACB)?

As of Fri May 17 2024, market cap of Pacific Biosciences of California is 552.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PACB stock?

You can check PACB's fair value in chart for subscribers.

What is the fair value of PACB stock?

You can check PACB's fair value in chart for subscribers. The fair value of Pacific Biosciences of California is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pacific Biosciences of California is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PACB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pacific Biosciences of California a good stock to buy?

The fair value guage provides a quick view whether PACB is over valued or under valued. Whether Pacific Biosciences of California is cheap or expensive depends on the assumptions which impact Pacific Biosciences of California's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PACB.

What is Pacific Biosciences of California's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PACB's PE ratio (Price to Earnings) is -1.86 and Price to Sales (PS) ratio is 2.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PACB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pacific Biosciences of California's stock?

In the past 10 years, Pacific Biosciences of California has provided -0.075 (multiply by 100 for percentage) rate of return.